456 related articles for article (PubMed ID: 10617473)
1. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.
Bell DW; Varley JM; Szydlo TE; Kang DH; Wahrer DC; Shannon KE; Lubratovich M; Verselis SJ; Isselbacher KJ; Fraumeni JF; Birch JM; Li FP; Garber JE; Haber DA
Science; 1999 Dec; 286(5449):2528-31. PubMed ID: 10617473
[TBL] [Abstract][Full Text] [Related]
2. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome.
Bougeard G; Limacher JM; Martin C; Charbonnier F; Killian A; Delattre O; Longy M; Jonveaux P; Fricker JP; Stoppa-Lyonnet D; Flaman JM; Frébourg T
J Med Genet; 2001 Apr; 38(4):253-7. PubMed ID: 11370630
[No Abstract] [Full Text] [Related]
3. Checkpoint gene linked to human cancer.
Hagmann M
Science; 1999 Dec; 286(5449):2433-4. PubMed ID: 10636795
[No Abstract] [Full Text] [Related]
4. Li-Fraumeni syndrome: the genetics and treatment considerations for the sarcoma and associated neoplasms.
Upton B; Chu Q; Li BD
Surg Oncol Clin N Am; 2009 Jan; 18(1):145-56, ix. PubMed ID: 19056046
[TBL] [Abstract][Full Text] [Related]
5. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation.
Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S
Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982
[TBL] [Abstract][Full Text] [Related]
6. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Vahteristo P; Tamminen A; Karvinen P; Eerola H; Eklund C; Aaltonen LA; Blomqvist C; Aittomäki K; Nevanlinna H
Cancer Res; 2001 Aug; 61(15):5718-22. PubMed ID: 11479205
[TBL] [Abstract][Full Text] [Related]
7. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
8. TP53, hChk2, and the Li-Fraumeni syndrome.
Varley J
Methods Mol Biol; 2003; 222():117-29. PubMed ID: 12710683
[TBL] [Abstract][Full Text] [Related]
9. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds.
Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K
Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970
[TBL] [Abstract][Full Text] [Related]
10. Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome.
Sodha N; Houlston RS; Bullock S; Yuille MA; Chu C; Turner G; Eeles RA
Hum Mutat; 2002 Dec; 20(6):460-2. PubMed ID: 12442270
[No Abstract] [Full Text] [Related]
11. Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
Manoukian S; Peissel B; Frigerio S; Lecis D; Bartkova J; Roversi G; Radice P; Bartek J; Delia D
Breast Cancer Res Treat; 2011 Nov; 130(1):207-15. PubMed ID: 21562711
[TBL] [Abstract][Full Text] [Related]
12. Screening hCHK2 for mutations.
Sodha N; Williams R; Mangion J; Bullock SL; Yuille MR; Eeles RA
Science; 2000 Jul; 289(5478):359. PubMed ID: 10939935
[No Abstract] [Full Text] [Related]
13. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.
Lee SB; Kim SH; Bell DW; Wahrer DC; Schiripo TA; Jorczak MM; Sgroi DC; Garber JE; Li FP; Nichols KE; Varley JM; Godwin AK; Shannon KM; Harlow E; Haber DA
Cancer Res; 2001 Nov; 61(22):8062-7. PubMed ID: 11719428
[TBL] [Abstract][Full Text] [Related]
14. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
[TBL] [Abstract][Full Text] [Related]
15. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations.
Delia D; Goi K; Mizutani S; Yamada T; Aiello A; Fontanella E; Lamorte G; Iwata S; Ishioka C; Krajewski S; Reed JC; Pierotti MA
Oncogene; 1997 May; 14(18):2137-47. PubMed ID: 9174049
[TBL] [Abstract][Full Text] [Related]
16. Three germline mutations in the TP53 gene.
Cornelis RS; van Vliet M; van de Vijver MJ; Vasen HF; Voute PA; Top B; Khan PM; Devilee P; Cornelisse CJ
Hum Mutat; 1997; 9(2):157-63. PubMed ID: 9067756
[TBL] [Abstract][Full Text] [Related]
17. Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk.
Varley J; Haber DA
Breast Cancer Res; 2003; 5(3):123-5. PubMed ID: 12793891
[TBL] [Abstract][Full Text] [Related]
18. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
Evans SC; Lozano G
Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
[TBL] [Abstract][Full Text] [Related]
19. Heterozygous TP53stop146/R72P fibroblasts from a Li-Fraumeni syndrome patient with impaired response to DNA damage.
De Moura J; Kavalec FL; Doghman M; Rosati R; Custodio G; Lalli E; Cavallari GM; Santa Maria J; Figueiredo BC
Int J Oncol; 2010 Apr; 36(4):983-90. PubMed ID: 20198344
[TBL] [Abstract][Full Text] [Related]
20. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
